Biotechnology All You Need to Know About BioNTech SE Sponsored ADR (BNTX) Rating Upgrade to Buy December 13, 2022
Biotechnology Fate Therapeutics Features Multiple Novel Approaches to Eliminate Conditioning Chemotherapy for Off-the-shelf, iPSC-derived Cell Therapies at 2022 ASH Annual Meeting December 13, 2022
Biotechnology CRISPR Therapeutics Provides Update on Its Ongoing Phase 1 CARBON(TM) Trial of CTX110® December 12, 2022
Biotechnology GT Biopharma and Fate Therapeutics Present Preclinical Data Highlighting Novel Dual Antigen Targeting Approach For The Treatment of AML at ASH 2022 December 12, 2022
Biotechnology Agios Presents Updated PYRUKYND® (mitapivat) Long-term Extension Data Demonstrating Sustained Clinical Benefits in Adults with Pyruvate Kinase (PK) Deficiency at 64th ASH Annual Meeting and Exposition December 11, 2022
Search
